Can Intellia Therapeutics cover its short-term obligations?

Its current ratio is 6.10 — current assets exceed current liabilities.

Where does Intellia Therapeutics's balance sheet data come from?

Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Intellia Therapeutics NTLA Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$155.46M-17.8%	$189.18M-16.6%	$226.75M-56.7%	$523.51M+324%
Short-term investments	$294.42M-28.6%	$412.33M-39.8%	$685.48M+2.4%	$669.12M+7.0%
Accounts receivable, net	$9.47M+11.2%	$8.52M-76.6%	$36.46M+868%	$3.77M+85.5%
Prepaid expenses and other current assets	$68.36M+129%	$29.83M-39.9%	$49.65M+143%	$20.41M+9.8%
Total current assets	$527.71M-17.5%	$639.86M-35.9%	$998.33M-18.0%	$1.22B+58.2%
Property and equipment, net	$17.67M-35.5%	$27.38M-16.4%	$32.76M+17.3%	$27.92M+33.2%
Operating lease right-of-use assets	$105.96M-51.7%	$219.29M+90.1%	$115.38M-13.3%	$133.08M+68.1%
Other non-current assets	$35.54M-19.7%	$44.26M+3.2%	$42.88M+5.8%	$40.53M+37.1%
Total assets	$842.13M-29.3%	$1.19B-8.5%	$1.3B-14.4%	$1.52B+17.4%
Accounts payable	$20.25M+38.8%	$14.59M+95.8%	$7.45M+44.6%	$5.15M-46.6%
Accrued expenses	$49.86M-9.9%	$55.36M-17.4%	$67.02M+10.1%	$60.88M+40.6%
Deferred revenue	$7.29M-64.7%	$20.66M-6.7%	$22.14M-49.5%	$43.84M-31.2%
Operating lease liabilities, current	$26.48M+30.8%	$20.25M+8.9%	$18.6M+11.5%	$16.69M+83.1%
Total current liabilities	$103.88M-6.3%	$110.85M-3.8%	$115.21M-9.0%	$126.55M+0.6%
Operating lease liabilities, non-current	$66.85M-64.8%	$189.95M+96.3%	$96.75M-15.1%	$114.02M+75.7%
Operating Lease Liabilities (Total)	$93.33M-55.6%	$210.2M+82.2%	$115.35M-11.7%	$130.7M+76.6%
Total liabilities	$170.73M-46.5%	$319.06M+27.2%	$250.81M-11.9%	$284.53M—
Common stock	$12K+20.0%	$10K+11.1%	$9K0.0%	$9K+28.6%
Additional paid-in capital	$3.26B+6.9%	$3.05B+12.5%	$2.71B+12.0%	$2.42B+38.6%
Retained earnings	-$2.59B-19.0%	-$2.18B-31.3%	-$1.66B-40.9%	-$1.18B-67.5%
Accumulated other comprehensive income (loss)	$1.03M+70.6%	$605K+127%	-$2.26M+69.7%	-$7.46M-183%
Total stockholders' equity	$671.39M-23.0%	$871.96M-17.0%	$1.05B-15.0%	$1.24B+18.8%
Total liabilities and stockholders' equity	$842.13M-29.3%	$1.19B-8.5%	$1.3B-14.4%	$1.52B+17.4%
Short- term Investments	$294.42M-28.6%	$412.33M-39.8%	$685.48M+2.4%	$669.12M+7.0%
Net Investment in Lease	$105.96M-51.7%	$219.29M+90.1%	$115.38M-13.3%	$133.08M+68.1%
Investments and sundry assets	$35.54M-19.7%	$44.26M+3.2%	$42.88M+5.8%	$40.53M+37.1%
Operating lease right-of-use assets	$105.96M-51.7%	$219.29M+90.1%	$115.38M-13.3%	$133.08M+68.1%
Operating Lease Right-of-Use Assets in Other Assets	$105.96M-51.7%	$219.29M+90.1%	$115.38M-13.3%	$133.08M+68.1%
Other Commercial Liabilities	$49.86M-9.9%	$55.36M-17.4%	$67.02M+10.1%	$60.88M+40.6%
Accrued Liabilities, Current	$49.86M-9.9%	$55.36M-17.4%	$67.02M+10.1%	$60.88M+40.6%
Total debt	$93.33M-55.6%	$210.2M+82.2%	$115.35M-11.7%	$130.7M+76.6%
Additional paid-in capital	$3.26B+6.9%	$3.05B+12.5%	$2.71B+12.0%	$2.42B+38.6%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$12K+20.0%	$10K+11.1%	$9K0.0%	$9K+28.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Intellia Therapeutics cover its short-term obligations?: Its current ratio is 6.10 — current assets exceed current liabilities.
Where does Intellia Therapeutics's balance sheet data come from?: Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.